EMA — authorised 14 December 2012
- Application: EMEA/H/C/002429
- Marketing authorisation holder: Genzyme Europe BV
- Local brand name: Kynamro
- Indication: treatment of cholesterol and hypercholesterolaemia
- Status: rejected
🇪🇺 Kynamro in European Union
EMA authorised Kynamro on 14 December 2012
Marketing authorisation
Kynamro in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in European Union
Frequently asked questions
Is Kynamro approved in European Union?
Yes. EMA authorised it on 14 December 2012.
Who is the marketing authorisation holder for Kynamro in European Union?
Genzyme Europe BV holds the EU marketing authorisation.